COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Outpatient Parenteral Antibiotic Therapy in the Metropolitan Area of Cologne

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04002453
Recruitment Status : Recruiting
First Posted : June 28, 2019
Last Update Posted : June 1, 2020
Information provided by (Responsible Party):
Clara Lehmann, University of Cologne

Brief Summary:

Many infectious diseases require a therapy that is administered intravenously due to a lack of oral treatments. Affected patients often have to stay weeks or even months in hospital just for receiving their therapy although they do not feel severely unwell.

Outpatient parenteral antibiotic therapy (OPAT) allows these patients under certain requirements to get discharged from hospital and apply the antibiotic treatment on their own. For these patients quality of life improves by feeling more comfortable at home and being able to participate in everyday life or even go back to work. For the hospitals a reduced inpatient health care means a clear reduction of costs.

The benefits of OPAT are obvious, shown by several studies, and in many countries e.g. the USA OPAT is a very well established way of treatment. In Germany however OPAT is used very infrequently and not in a standardized manner. This is probably due to inadequate knowledge of this form of treatment and deficits in the outpatient care structure, as OPAT is not reflected in the remuneration system of the German health care system despite internationally proven benefits.

The aim of this study is to identify and analyze possible obstacles to the implementation of OPAT into the standard patient care in Germany regarding financial, structural and medical limitations. Therefore the investigators intend to treat 120 patients in the metropolitan area of Cologne with OPAT and observe effectiveness, safety, logistics and acceptance to this kind of therapy.

If successful, the project should help to identify the potential of OPAT for Germany. If positive effects and feasibility can be demonstrated in the Cologne metropolitan region, OPAT could become an important therapy option with many advantages for certain patients.

Condition or disease Intervention/treatment
Implementation of OPAT in Germany Procedure: Outpatient Parenteral Antibiotic Therapy

Layout table for study information
Study Type : Observational [Patient Registry]
Estimated Enrollment : 120 participants
Observational Model: Case-Only
Time Perspective: Prospective
Target Follow-Up Duration: 6 Weeks
Official Title: Outpatient Parenteral Antibiotic Therapy in the Metropolitan Area of Cologne
Actual Study Start Date : October 1, 2019
Estimated Primary Completion Date : August 15, 2021
Estimated Study Completion Date : September 30, 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Antibiotics

Group/Cohort Intervention/treatment
Outpatient parenteral antimicrobial therapy
Patients with an infectious disease that receive an outpatient parenteral antimicrobial therapy
Procedure: Outpatient Parenteral Antibiotic Therapy
Application of outpatient parenteral antibiotic therapy in patients with infectious diseases to allow them to get discharged from hospital.

Primary Outcome Measures :
  1. Number of Patients with effective OPAT [ Time Frame: 12 weeks ]
    Successful administration and completion of the antiinfective therapy

  2. Number of Patients With Treatment-Related Adverse Events [ Time Frame: 12 weeks ]
    side-effetcs of treatment and catheter-related infections

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
primary care clinic, university hospital

Inclusion Criteria:

  • patients who get OPAT

Exclusion Criteria:

  • patients who don't get OPAT or are not capable to give their informed consent

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04002453

Layout table for location information
University of Cologne Recruiting
Cologne, Germany, 50937
Contact: Clara Lehmann, MD    +4922147888835   
Principal Investigator: Lehmann Clara, MD         
Sponsors and Collaborators
University of Cologne
Layout table for additonal information
Responsible Party: Clara Lehmann, Head of outpatient clinic, University of Cologne Identifier: NCT04002453    
Other Study ID Numbers: C-OPAT
First Posted: June 28, 2019    Key Record Dates
Last Update Posted: June 1, 2020
Last Verified: May 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Clara Lehmann, University of Cologne:
infectious diseases
Additional relevant MeSH terms:
Layout table for MeSH terms
Anti-Bacterial Agents
Anti-Infective Agents